July 8, 2020 – Philips Healthcare and Leeds Teaching Hospitals NHS Trust announced a seven-year managed service agreement to deliver on the Trusts’ vision to set new standards of excellence for cardiac care in the U.K. and globally. The partnership will combine the latest innovations in technology for integrated cardiovascular solutions. The aim of the partnership is better health outcomes, lower cost of care and an improved experience for patients and staff.

July 7, 2020 – MedAlliance announced enrollment of the first patient in its study of Selution SLR 0.014 drug-eluting balloon (DEB) for the treatment of in-stent restenosis (ISR). This is the first DEB accepted by the FDA for its breakthrough program. The Selution SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES).

July 7, 2020 – Medtronic announced it received U.S. Food and Drug Administration (FDA) clearance and European CE mark approval for its Linq II insertable cardiac monitor (ICM) with remote programming, which enables clinicians to optimize device settings without the need for patients to return to the office or hospital.

July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major adverse outcomes, including death, compared to white patients.